Non-vitamin K antagonist oral anticoagulants (NOAC) in nonvalvular atrial fibrillation – in-group comparison

Adam Piasecki

doi:10.56782/pps.36

Published : 2022-07-20

Vol. 20 No. 1 (2022)

Non-vitamin K antagonist oral anticoagulants (NOAC) in nonvalvular atrial fibrillation – in-group comparison

Adam Piasecki

DOI: https://doi.org/10.56782/pps.36

Abstract

Atrial fibrillation (AF) is a major and widespread health problem. Its main and most threatening complication, ischemic stroke, is responsible for a great number of deaths and disability worldwide. This makes anticoagulation a priority in AF management. Non-vitamin K antagonist oral anticoagulants (NOAC) are currently the most effective and safe option for patients with nonvalvular atrial fibrillation. Rivaroxaban, apixaban, edoxaban and dabigatran are non-inferior to warfarin in terms of stroke and systemic embolism prevention. However, warfarin use is associated with higher rates of major bleedings than any NOAC. Different drugs and mechanism of action among NOACs may result in differences in terms of efficacy and safety between them. This review aims to assess these differences by summarizing data available in online databases and European Society of Cardiology guidelines. There are major studies comparing each of NOACs to warfarin, however there is only limited data comparing apixaban, rivaroxaban and dabigatran directly. Both direct and indirect comparisons suggest that apixaban, rivaroxaban and dabigatran use is associated with similar reduction of stroke and systemic embolism risk. In terms of safety, anticoagulation with apixaban results in lower major bleeding risk relative to dabigatran and rivaroxaban.

Keywords:

atrial fibrillation, apixaban, dabigatran, rivaroxaban, anticoagulants

Most read articles by the same author(s)

Adam Piasecki, Magdalena Sitnik, Jakub Olszewski, Maciej Bara, Katarzyna Herjan, Piotr Armański, The changing landscape of mineralocorticoid receptor antagonists – finerenone in cardiovascular and renal health , Prospects in Pharmaceutical Sciences: Vol. 22 No. 1 (2024)

Details

References

Statistics

Authors

Download files

PDF

Citation rules

Piasecki, A. (2022). Non-vitamin K antagonist oral anticoagulants (NOAC) in nonvalvular atrial fibrillation – in-group comparison. Prospects in Pharmaceutical Sciences, 20(1), 26–31. https://doi.org/10.56782/pps.36

Altmetric indicators

Cited by / Share

Licence

This work is licensed under a Creative Commons Attribution 4.0 International License.

References

Hindricks, G., et al., 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibril-lation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Asso-ciation (EHRA) of the ESC. Eur Heart J, 2021. 42(5): p. 373-498. DOI: https://doi.org/10.1093/eurheartj/ehaa945

Wan, Y., et al., Anticoagulation control and prediction of adverse events in patients with atrial fibrillation: a systematic review. Circ Cardiovasc Qual Outcomes, 2008. 1(2): p. 84-91. DOI: https://doi.org/10.1161/CIRCOUTCOMES.108.796185

Johnson, J.A. and L.H. Cavallari, Warfarin pharmacogenetics. Trends Cardiovasc Med, 2015. 25(1): p. 33-41. DOI: https://doi.org/10.1016/j.tcm.2014.09.001

EMA. Charakterystyka Produktu Leczniczego Xarelto. Available from: https://www.ema.europa.eu/en/documents/product-information/xarelto-epar-product-information_en.pdf.

EMA. Charakterystyka Produktu Leczniczego Eliquis. Available from: https://www.ema.europa.eu/en/documents/product-information/eliquis-epar-product-information_en.pdf.

EMA. Charakterystyka Produktu Leczniczego Pradaxa. Available from: https://www.ema.europa.eu/en/documents/product-information/pradaxa-epar-product-information_en.pdf.

EMA. Charakterystyka Produktu Leczniczego Lixiana. Available from: https://www.ema.europa.eu/en/documents/product-information/lixiana-epar-product-information_en.pdf.

Eriksson, B.I., et al., Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med, 2008. 358(26): p. 2765-75. DOI: https://doi.org/10.1056/NEJMoa0800374

Lassen, M.R., et al., Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med, 2008. 358(26): p. 2776-86. DOI: https://doi.org/10.1056/NEJMoa076016

Patel, M.R., et al., Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med, 2011. 365(10): p. 883-91. DOI: https://doi.org/10.1056/NEJMoa1009638

Granger, C.B., et al., Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med, 2011. 365(11): p. 981-92. DOI: https://doi.org/10.1056/NEJMoa1107039

Giugliano, R.P., et al., Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med, 2013. 369(22): p. 2093-104. DOI: https://doi.org/10.1056/NEJMoa1310907

Connolly, S.J., et al., Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med, 2009. 361(12): p. 1139-51. DOI: https://doi.org/10.1056/NEJMoa0905561

Huisman, M.V., et al., The Changing Landscape for Stroke Prevention in AF: Findings From the GLORIA-AF Registry Phase 2. J Am Coll Cardiol, 2017. 69(7): p. 777-785. DOI: https://doi.org/10.1016/j.jacc.2016.11.061

Staerk, L., et al., Non-vitamin K antagonist oral anticoagulation usage according to age among patients with atrial fibrillation: Temporal trends 2011-2015 in Denmark. Sci Rep, 2016. 6: p. 31477. DOI: https://doi.org/10.1038/srep31477

Haas, S., et al., Predictors of NOAC versus VKA use for stroke prevention in patients with newly diagnosed atrial fibrillation: Results from GARFIELD-AF. Am Heart J, 2019. 213: p. 35-46. DOI: https://doi.org/10.1016/j.ahj.2019.03.013

Mantha, S. and J. Ansell, An indirect comparison of dabigatran, rivaroxaban and apixaban for atrial fibrillation. Thromb Haemost, 2012. 108(3): p. 476-84. DOI: https://doi.org/10.1160/TH12-02-0093

Noseworthy, P.A., et al., Direct Comparison of Dabigatran, Rivaroxaban, and Apixaban for Effectiveness and Safety in Nonvalvular Atrial Fibrillation. Chest, 2016. 150(6): p. 1302-1312. DOI: https://doi.org/10.1016/j.chest.2016.07.013